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Abstract
Background: Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7%.
Our study’s objective was to delineate the evidence on the epidemiology of HCV infection among the different
population groups in Egypt, and to draw analytical inferences about the nature of HCV transmission in this country.
Methods: We conducted a systematic review of all data on HCV prevalence and incidence in Egypt following
PRISMA guidelines. The main sources of data included PubMed and Embase databases. We also used a multivariate
regression model to infer the temporal trend of HCV prevalence among the general population and high risk
population in Egypt.
Results: We identified 150 relevant records, four of which were incidence studies. HCV incidence ranged from 0.8 to
6.8 per 1,000 person-years. Overall, HCV prevalence among pregnant women ranged between 5-15%, among blood
donors between 5-25%, and among other general population groups between 0-40%. HCV prevalence among
multi-transfused patients ranged between 10-55%, among dialysis patients between 50-90%, and among other high
risk populations between 10% and 85%. HCV prevalence varied widely among other clinical populations and
populations at intermediate risk. Risk factors appear to be parenteral anti-schistosomal therapy, injections, transfusions,
and surgical procedures, among others. Results of our time trend analysis suggest that there is no evidence of a
statistically significant decline in HCV prevalence over time in both the general population (p-value: 0.215) and high risk
population (p-value: 0.426).
Conclusions: Egypt is confronted with an HCV disease burden of historical proportions that distinguishes this nation
from others. A massive HCV epidemic at the national level must have occurred with substantial transmission still
ongoing today. HCV prevention in Egypt must become a national priority. Policymakers, and public health and medical
care stakeholders need to introduce and implement further prevention measures targeting the routes of HCV
transmission.
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Background
The Egyptian Demographic Health Survey (EDHS), a
cross sectional survey including hepatitis C virus (HCV)
biomarkers, was conducted in 2008 on a large nationally
representative sample [1]. It estimated HCV prevalence
among the 15–59 years age group to be 14.7% [1].
Accordingly, Egypt has the highest HCV prevalence
in the world [2-4]. This unparalleled level of exposure
to this infection appears to reflect a national level
epidemic. It has been postulated that the epidemic
has been caused by extensive iatrogenic transmission
during the era of parenteral-antischistosomal-therapy
(PAT) mass-treatment campaigns [5,6]. Today, HCV
infection and its complications are among the leading
public health challenges in Egypt [7].
Multiple community- and facility-based studies were
conducted among different population groups in Egypt
over the last two decades to assess the distribution of
infection in the population. These studies have immensely
improved our understanding of HCV epidemiology in
Egypt. Nevertheless, two lingering and critical questions
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regarding HCV transmission in Egypt are yet to be
addressed satisfactorily:
1) Does the high HCV prevalence reflect mainly
historical exposures during the PAT campaigns before
1985, with limited current infection incidence?
2) If not, to what extent is HCV transmission still
ongoing, and what are the drivers, risk factors, and
modes of this transmission?
The objective of our study is to attempt, at least in part,
to address these two questions through a comprehensive
systematic review and integrated analysis of multiple
sources of data about HCV prevalence and incidence in
Egypt. Our study examined side-by-side information col-
lected by different methods, by different investigators, and
in different populations, allowing us to corroborate hy-
potheses across datasets, thereby reducing the impact of
potential biases that can exist in a single study, dataset, or
line of evidence. Our approach also facilitated an identifi-
cation of the key research, policy, and programming prior-
ities that require further investigation and consideration.
Methods
Data sources and search strategy
We conducted a systematic review of the prevalence and
incidence of HCV in the different population groups in
Egypt following the PRISMA guidelines [8]. The PRISMA
checklist can be found in Table S1, see Additional file 1.
The main data sources for this investigation were:
PubMed (Medline) and Embase databases. The above data
sources were searched with no time or language restric-
tions. PubMed and Embase were searched using both
MeSH/Emtree terms, respectively, and text terms. MeSH/
Emtree terms were exploded to cover all subheadings.
Details of the search criteria for each of these databases
can be found below:
PubMed: ((“Hepatitis C”[Mesh] OR “Hepatitis C
Antibodies”[Mesh] OR “Hepatitis C Antigens”[Mesh]
OR “Hepacivirus”[Mesh] OR “Hepatitis C, chronic/
epidemiology”[Mesh] OR “Hepatitis C, chronic/etiology”
[Mesh] OR “Hepatitis C, chronic/transmission”[Mesh] OR
“Hepatitis C, chronic/virology”[Mesh] OR “Hepatitis
C”[Text] OR “HCV”[Text]) AND (“Egypt”[Mesh] or Egypt
[Text])).
Embase: (egypt.mp. or exp Egypt/) and (exp hepatitis C/
or exp Hepatitis C virus/ or hepatitis C.mp. or HCV.mp.
or hepacivirus.mp.).
Ethics statement
Our study did not need an ethics committee approval or
written informed consent because it relies entirely on
published data.
Study selection
The results of the searches were imported to a reference
manager, Endnote, where duplicate publications were iden-
tified and excluded. The remaining unique and potentially
relevant records were then imported into Microsoft Excel
where screening for relevance and eligibility took place.
The titles and abstracts of all records retrieved were
screened for relevance independently by two of the authors
(YM and SR). Screening for relevance was conducted in
two stages: 1) Stage 1 involved screening all titles and
abstracts to exclude all non-relevant articles; 2) Stage 2
involved retrieving and screening the full-text of all articles
deemed relevant after the initial abstract screening, to
further exclude any remaining non-eligible articles.
Inconsistencies between reviewers were discussed and
sorted out by consensus.
A publication was considered eligible for inclusion in
the review if it had data on at least one of the following
outcomes of interest: 1) prevalence of HCV as detected
by HCV antibodies; and 2) incidence of HCV as detected
by HCV antibodies. Only studies reporting primary data
were included. Reviews of literature were excluded, but
all data reported were checked and compared to the
results of our search. Any additional study identified in
the excluded review and not retrieved by our search was
identified and added to our review. Case reports and
case series were excluded. All other study designs were
eligible for inclusion. Distinction was made between the
number of “reports” (actual publications i.e. papers,
conference abstracts etc.) and the number of “studies”
(actual study and research project). Multiple reports of the
same study were identified as duplicates and counted as
one study.
Eligible studies were then categorized into two types:
prevalence studies and incidence studies. Any article
reporting both the prevalence and incidence of HCV
was counted as two studies, one for incidence and one
for prevalence. Results were then pooled into one list
containing all eligible and unique studies.
Data extraction and population classification
The following data were then extracted from each eligible
study included in the review: author, year of data collec-
tion, year of publication, city, study site, study design,
sampling technique, population (blood donors, barbers,
health care workers, injecting drug users (IDUs) etc.),
socio-demographic characteristics of the population
(sex, age, rural vs. urban etc.), sample size, and prevalence
and/or incidence of HCV. Although our search criteria
did not specifically target publications reporting HCV
RNA prevalence or risk factors in Egypt, we extracted this
information from eligible publications when available. Risk
factors were extracted only if they were statistically
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significant in a multivariate regression analysis within a
study that was found relevant according to our search
criteria.
Data on the above mentioned indicators were extracted
from included records and entered into a computerized
database on Microsoft Excel. Extracted data were then
classified and analyzed on the basis of the study popula-
tion’s risk of acquiring HCV. The four defined major
population risk groups are:
1) Populations at direct or high risk: this group
includes IDUs, multi-transfused patients such as
hemophiliacs and thalassemics, dialysis patients, and
viral hepatitis patients, among others.
2) Populations at indirect or intermediate risk: this group
includes familial contacts of HCV patients i.e. their
children, spouses, and other household contacts;
select practitioners of professions at risk of HCV such
as dentists, healthcare workers and barbers;
populations with potential IDU exposures including:
prisoners and HIV patients; and populations with
health facility/injecting exposures such as diabetic
patients and hospitalized populations.
3) General population groups (populations which are
not at an elevated risk of HCV exposure): pregnant
women, blood donors, children, rural populations,
army recruits or fire brigade personnel, outpatient
clinic attendees, populations defined in case–control
studies as healthy populations (controls), among
other groups categorized together as “other general
population” groups.
4) Special clinical population groups such as Hodgkin’s
lymphoma (HL) patients, lichen planus (LP), and
liver disease patients, among others. This category
includes patients with specific diseases that require
clinical care, and thus can be exposed to HCV in
medical care facilities, though at variable levels of
risk that is difficult to categorize among any of the
above mentioned population groups.
Within any specific category of the above population
groups, considerable heterogeneity and different sub-
group trends may exist.
In order to create prevalence figures, HCV prevalence
measures within each of the population groups above
were stratified into two strata: pre-2001 and post-2001,
based on the year in which the study was conducted. The
year 2001 was chosen as the cut-off year, as this was the
year in which the Egyptian Ministry of Health initiated
broad infection control programs in the country [9].
Time trend analysis
We conducted a time trend analysis investigating the
change in HCV prevalence among the general population
and high risk population in Egypt with respect to time.
We started by conducting univariate linear regression
analyses examining the change in HCV prevalence over
time in each of the general population subgroups separately.
A similar analysis was conducted in each of the high risk
population subgroups. To avoid systematic biases in any
one subgroup and to increase the statistical power of the
time trend analysis, we also used a multivariate linear
regression model estimating the temporal trend in HCV
prevalence, while adjusting for the different subgroups
in each population grouping. Two such models were
performed: one for the general population and the other
for the high-risk population. Mean HCV prevalence was
modeled using a model that includes as predictors: time
(in years) and the different general population subgroups
(or high risk population subgroups).
The general population regression model stipulates
that:
Mean HCV Prevalence ¼ β0 þ β1  Time
þ β2  Antenatal clinic attendees
þ β3  Blood donors þ β4  Rural village residents
þ β5  Childrenþ β6 Healthy populations
þ β7  Army recruits þ β8 Other
Similarly, the high risk population regression model
stipulates that:
Mean HCV Prevalence ¼ β0 þ β1  Time
þ β2 Multi transfused patients
þ β3  Schistosomiasis patients
þ β4  Thalassemic patients
þ β5  Viral hepatitis patients
In both models, βi are the parameters of the statistical
model and Time and sub-population names are the
indicator variables.
Data used for these analyses were extracted from the
eligible studies included in this review. In the presence
of both an overall HCV prevalence measure as well as
stratified prevalence measures, we included only the
overall prevalence measure. Including both overall and
stratified prevalence measures from the same study
would have given more weight to those studies, relative
to others, thereby biasing our results. The year of data
collection was estimated for studies missing this variable.
This was done by conducting a correlation analysis
between the year of data collection and the year of
publication for studies having data on both, followed by a
paired t-test to estimate the mean difference between them.
We then applied this difference to the year of publication
to estimate the year of data collection when missing.
Midpoints were calculated and used for studies conducted
over a number of years. The statistical analysis was
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The study selection process is described in Figure 1, as
adapted from the PRISMA 2009 flow diagram [8]. The
number of records retrieved through both PubMed and
Embase was 1,146 as of August 1, 2012, out of which
445 were excluded as duplicates. After assessing all
documents according to their titles and abstracts, the
full-text of 183 records were retrieved for screening in
addition to 11 papers identified through references of
reviews. Of those, 150 records were found eligible for
inclusion in the present article. Only one relevant record
was identified outside the PubMed and Embase search;
the EDHS [1]. No single report has reported both a
relevant incidence measure and a relevant prevalence
measure.
HCV incidence
Five incidence measures were identified through our
search, reported in four incidence reports (Table 1). All
studies were conducted in rural areas of Egypt among
village residents, pregnant women, and children [10-13].
Overall high HCV incidence rates were observed in these
studies ranging from 0.8 to 6.8 per 1,000 person-years.
Figure 1 Flow of article selection for the HCV prevalence and incidence in Egypt search. This chart, adapted from the PRISMA 2009 flow
diagram, displays the flow of article selection for the HCV incidence and prevalence in Egypt search of scientific databases, namely PubMed
and Embase.
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Prevalence of HCV in the general population
Sixty-nine studies reported HCV prevalence in the general
population. Details are shown in Table 2. HCV prevalence
among the general population of Egypt is documented to
be very high. The 2008 EDHS measured HCV prevalence
to be 14.7% among a nationally representative sample of
11,126 Egyptians aged 15–59 years old [1]. The diverse
HCV studies conducted among different general popula-
tion subgroups, regardless of design or methodology,
consistently report a very high HCV prevalence, as high as
41% in some studies [10]. Overall, the prevalence appears
to increase dramatically with age with the highest rates
observed among populations aged greater than 40 years.
A number of studies were conducted among blood
donors. A higher prevalence is observed among paid blood
donors and family replacement blood donors compared to
voluntary donors [10-12]. Male blood donors had a higher
prevalence than their female counterparts [13]. Blood
donors from rural areas had a higher prevalence than those
from urban areas [38].
Multiple studies were conducted among village resi-
dents in high HCV prevalence areas (Table 2). The overall
prevalence in rural areas averaged about 20%, higher than
the national average. A study conducted in Kalama, a
village in the Nile Delta, reported HCV prevalence of 40%
among village residents [60]. Similar to blood donor
studies, village residents were shown to have a higher
prevalence among males compared to females [62,81],
and a marked growth in prevalence with age [56,58,59].
A study conducted in 1997, among 3,993 residents of a
village in the Nile Delta region, observed prevalence
rates in children, ages 0–19, ranging between 7 and
9.9%. This rate increased to 27.6% in those 20–39 years
and more than doubled to 56.7% among village residents
greater than 40 years of age [82].
High HCV prevalence was also observed among pregnant
women and children in Egypt. Recent studies conducted
among pregnant women reported a prevalence of about 8%
in Assuit [27] and Benha [28], and as high as 15.8% in rural
villages of the Nile Delta [26]. Studies conducted among
rural school children reported an average prevalence of
about 7% [53,66,68,69], while the average prevalence in
children attending outpatient clinics was found to be
approximately 4% [18,19,21,22]. High prevalence was
also observed among select subgroups such as tourism
workers [70], army recruits [53,79] and fire brigade
personnel [34].
Figure 2A depicts the range of prevalence within each
subgroup in studies conducted pre- and post-2001.
Among blood donors, studies appear to cluster at lower
HCV prevalence levels post- 2001 infection control
programs, compared to pre-2001. However, no distinct
pattern can be observed within each of the other
subgroups.
Prevalence of HCV among populations at direct or high
risk of exposure
We classified populations at direct or high risk of HCV ex-
posure into six subcategories: viral hepatitis patients, multi-
transfused patients, thalassemia patients, schistosmiasis
patients, patients on hemodialysis and IDUs. Table 3 lists
all the studies in each sub-category and the reported
prevalence measures.
Among patients diagnosed with acute viral hepatitis,
HCV prevalence ranged from as low as 4.3% [89] to as
high as 78.7% [85]. Once more, we observed a higher
prevalence among studies conducted in rural populations
versus urban populations. A recent study conducted in
2010 reported an HCV prevalence of 8.7% among children
with viral hepatitis [87].
The majority of studies in multi-transfused and thalas-
semia patients were conducted among children. High
HCV prevalence rates were observed with averages of
about 42% among multi-transfused children and about
58% among children with thalassemia. Multiple studies
were also conducted among hemodialysis patients (mostly
adults). Very high HCV prevalence was found in both
adult populations and children on hemodialysis.
There were six studies that investigated HCV prevalence
among schistosomiasis patients. Of these, only two expli-
citly mentioned previous PAT exposure. However, from the
studies context, and given the high HCV prevalence across
all of these studies, exposure to previous PAT campaigns
seems to be implicitly assumed. Accordingly, we chose to
classify these six studies in one subgroup: schistosomiasis
patients, and not separate them into two categories based
on previous PAT exposure.
Table 1 Studies reporting hepatitis C virus incidence in Egypt
Citation Year Location Study population Sample size Incidence (per 1,000
person-years)
Mohamed,05 [14] 1997-2000 Qalubyia, Lower Egypt Village residents 2,463 6.8
Mohamed,05 [14] 1997-2000 Assuit, Upper Egypt Village residents 4,275 0.8
Saleh,08 [15] 1997-2006 Menoufia, Lower Egypt Pregnant women 2,177 5.2
Mostafa,10 [16] 2001-2003 Menoufia, Lower Egypt Village residents 3,580 2.4
Saleh,10 [17] 2000-2006 Menoufia, Lower Egypt Children of 3 villages with high prevalence of HCV 2,852 2.7
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Table 2 Studies reporting hepatitis C virus prevalence among the general population in Egypt
Citation Year Location Sampling Population characteristic Sample size Sero-prevalence RNA prevalence
Outpatient clinic attendees
Khalifa,93 [18] 1990-1 Cairo city, Cairo CS Children 84 0.0% N/A
El-Nanawy,95 [19] N/A Alexandria city, Alexandria CS Children 110 11.8% N/A
Miras,02 [20] N/A Tanta, Gharbia, Lower Egypt CS In/out-patient children living in HCV
endemic region
105 0.0% N/A
El-Raziky,07 [21] 2004 Cairo city, Cairo CS Children 1–9 yrs old 1,042 1.4% 0.5%
Kandil,07 [22] 2004-6 Cairo city, Cairo CS Healthy children 20 5.0% N/A
Antenatal clinic attendees
Hassan,93 [23] N/A N/A CS 1,536 4.3% N/A
Agha,98 [24] 1996-7 Mansoura, Dakahlia, Lower Egypt CS 767 13.7% 23.7%
Kassem,00 [25] 1996 Alexandria city, Alexandria CS 100 19.0% 14.0%
Stoszek,05 [26] 1997-03 3 rural villages in Nile River Delta, Lower Egypt CS 2,587 15.8% 10.8%
Zahran,10 [27] 2008-9 Assuit, Upper Egypt CS 500 8.0% 7.4%
Abdulqawi,10 [28] 2003-8 Benha, Qalubiya, Lower Egypt CS 1,224 8.6% 6.8%
Abo Elmagd,11 [29] N/A N/A CS 20-40 year old mothers 61 13.0% N/A
Blood donors
Kamel,92 [30] 1992 Cairo city, Cairo CS Male university students, 20–27 years 2,164 9.7% N/A
El-Zayadi,92 [31] N/A N/A CS 76 5.2% N/A
Darwish,92 [32] N/A N/A CS 90 14.4% N/A
Darwish,93 [33] 1992 Cairo city, Cairo CS 163 13.6% N/A
El-Ahmady,94 [10] N/A N/A CS Paid blood donors 99 35.4% N/A
Quinti,95 [34] 1992-4 Alexandria city, Alexandria CS 283 20.8% N/A
Bassily,95 [35] N/A Cairo city, Cairo CS 188 26.6% N/A
El Gohary,95 [36] 1990-2 Suez city, Suez and Ismailia, Lower Egypt CS 1,187 14.5% N/A
Attia,96 [37] N/A Cairo city, Cairo CS 156 21.8% N/A
Arthur,97 [38] 1993 24 Governorates CS 2,644 24.8% N/A
El-Zayadi,97 [39] N/A N/A CS 180 9.4% N/A
Gad,01 [40] 1998 Ismailia, Lower Egypt CS 20 20.0% N/A
Tanaka,04 [41] 1999 13 governorates, Upper and Lower Egypt CS 3,608 8.8% 6.2%
Hashish,05 [42] N/A Alexandria city, Alexandria CS 95 23.2% N/A
El-Gilany,06 [43] 2002-3 Mansoura, Dakahlia, Lower Egypt CS Student voluntary blood donors 2,157 2.7% N/A
Agha,06 [44] N/A N/A CS 2,400 8.0% N/A





















Table 2 Studies reporting hepatitis C virus prevalence among the general population in Egypt (Continued)
El-Zayadi,08 [46] 2005 26 governorates Random All blood donors 760 5.0% N/A
El-Zayadi,08 [46] 2005 26 governorates Female blood donors 124 6.5% N/A
El-Zayadi,08 [46] 2005 26 governorates Male blood donors 636 4.7% N/A
Ismail,09 [47] 2000-7 Mansoura, Dakahlia, Lower Egypt CS 55,922 12.0% N/A
Ashour,09 [48] 2006-8 8 governorates CS 515,758 4.8% N/A
Elkareh,09 [11] 2008 Menoufia, Lower Egypt CS Family replacement blood donors 4,709 12.7% N/A
Elkareh,09 [11] 2008 Menoufia, Lower Egypt CS Blood donors 3,569 6.3% N/A
Elkareh,09 [11] 2008 Menoufia, Lower Egypt CS Family replacement blood donors 8,705 14.6% N/A
Elkareh,09 [11] 2008 Menoufia, Lower Egypt CS Blood donors 414 8.7% N/A
Rushdy,09 [13] 2006-7 Suez Canal area CS All blood donors 9,150 5.6% N/A
Rushdy,09 [13] 2006-7 Suez Canal area Male blood donors 7,155 2.9% N/A
Rushdy,09 [13] 2006-7 Suez Canal area Female blood donors 1,995 1.7% N/A
Eita,09 [12] 2005-8 Dakhilia, Lower Egypt CS Voluntary blood donors 73,431 4.6% N/A
Eita,09 [12] 2005-8 Dakhilia, Lower Egypt CS Family blood donors 113,504 5.5% N/A
Khattab,10 [36] 2000-8 Minya, Lower Egypt CS 211,772 9.0% N/A
Radwan,10 [49] 2009 N/A CS 27,537 4.0% N/A
Wasfi,11 [50] 2007-8 Alexandria city, Alexandria CS 3,420 3.5% N/A
Awadalla,11 [51] N/A Cairo city, Cairo CS 1,000 16.8% N/A
Farawela,12 [52] 2010-1 Cairo city, Cairo CS 100 5% N/A
Rural village residents
Abdel-Wahab,94 [53] 1992 Menoufia, Lower Egypt CS 270 18.1% N/A
Kamel,94 [54] 1992 Sada, Kafr El Sheikh, Lower Egypt All village
residents
1,259 15.9% N/A
El Gohary,95 [36] 1990-2 Suez Canal area CS Healthy blood volunteers resident to
rural area with high schistosomiasis
271 14.4% N/A
El Gohary,95 [36] 1990-2 North Sinai, frontier CS Bedouin population with low schistosomiasis 148 15.5% N/A
Darwish,95 [55] N/A N/A CS Healthy villagers and non-professional blood
donors
188 21.8% N/A
Darwish,96 [56] 1994 Kalama, Qaluobyia, Lower Egypt CS Village residents:1–3 years 12 0.0% N/A
Darwish,96 [56] 1994 Kalama, Qaluobyia, Lower Egypt CS Village residents: 4–9 years 21 0.0% N/A
Darwish,96 [56] 1994 Kalama, Qaluobyia, Lower Egypt CS Village residents: 10–19 years 46 8.0% N/A
Darwish,96 [56] 1994 Kalama, Qaluobyia, Lower Egypt CS Village residents: 20–39 years 29 20.0% N/A
Darwish,96 [56] 1994 Kalama, Qaluobyia, Lower Egypt CS Village residents: 40–67 years old 47 51.0% N/A























Table 2 Studies reporting hepatitis C virus prevalence among the general population in Egypt (Continued)
Nafeh,00 [58] N/A Assuit, Upper Egypt CS Village residents≥ 5 years of age (overall) 6,031 8.7% 5.4%
Nafeh,00 [58] N/A Assuit, Upper Egypt CS Village residents ≤30 years 4,164 3.6% 2.0%
Nafeh,00 [58] N/A Assuit, Upper Egypt CS Village residents >30 years 1,867 20.0% 12.9%
Abdel-Aziz,00 [59] 1997 Aghour El Soughra, Qaluobyia, Lower Egypt CS Village residents ≥5 years old (overall) 3,999 24.3% 14.8%
Abdel-Aziz,00 [59] 1997 Aghour El Soughra, Qaluobyia, Lower Egypt CS Village residents: ≤20 years 2,105 9.3% N/A
Abdel-Aziz,00 [59] 1997 Aghour El Soughra, Qaluobyia, Lower Egypt CS Village residents >20 years 1,894 41.0% N/A
Darwish,01 [60] 1994-5 Kalama, Qaluobyia, Lower Egypt CS Village residents >10 years of age 796 40.0% N/A
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt CS 842 27.4% 7.4%
Arafa,05 [62] 2002-3 Zawiat Razin, Menoufia, Lower Egypt CS 4,020 11.8% N/A
Arafa,05 [62] 2002-3 Zawiat Razin, Menoufia, Lower Egypt CS Village residents: under 20 years old 1,759 2.8% N/A
Arafa,05 [62] 2002-3 Zawiat Razin, Menoufia, Lower Egypt CS Village residents: 20 and over years old 2,252 18.9% N/A
Mohamed,06 [63] 2002 Zawiat Razin, Menoufia, Lower Egypt CS Village residents 18–65 years of age 2,425 18.5% N/A
Eassa,07 [64] 2006-7 Zagazig district, Sharkia, Lower Egypt CS Village households 304 10.9% N/A
Aguilar,08 [65] N/A Fakkous and 8 surrounding villages CS Village residents: males 78 51.3% 38.5%
Aguilar,08 [65] N/A Fakkous and 8 surrounding villages,
Sharkia, Lower Egypt
CS Village residents: females 81 42.0% 29.6%
Children
Abdel-Wahab,94 [53] 1992 Menoufia, Lower Egypt CS Rural male primary school children 190 12.1% N/A
El-Sherbini,03 [66] 1994 N/A CS Village school children 6–15 years old 294 5.8% 2.4%
Mohamed,06 [67] 1997 Nile River Delta, Lower Egypt CS Village children 5–18 years old 1,823 8.2% N/A
Mohamed,06 [67] 1997 Assuit, Upper Egypt CS Village children 5–18 years old 2,808 2.5% N/A
El Sherbini,07 [68] 2002 Tanta, Gharbia, Lower Egypt CS School children 470 2.1% 0.8%
Barakat,11 [69] 2005 Alexandria city, Alexandria PBS School children 500 5.8% 4.4%
Healthy individuals
El-Sayed,96 [70] 1994 South Sinai, frontier CS Tourism workers 740 14.3% N/A
Mohamed,96 [71] N/A N/A CS Egyptians applying for work abroad 5,071 31.5% N/A
Mohamed,96 [71] N/A N/A CS Egyptians applying for work abroad: Females N/A 13.2% N/A
Mohamed,96 [71] N/A N/A CS Egyptians applying for work abroad: Males N/A 34.0% N/A
Gohar,95 [72] N/A N/A CS 15 13.3% N/A
Halim,99 [73] 1996 Cairo city, Cairo CS Healthy staff of the university 50 6.0% N/A
Hassan,01 [74] 1995-6 Cairo city, Cairo CS Healthy individuals visiting hospitalized friends 35 42.9% N/A
Strickland,02 [75] N/A Nile River Delta, Lower Egypt CS 212 46.7% 36.3%
El-sayed,06 [76] 2002 Cairo city, Cairo CS 36 8.3% 2.8%





















Table 2 Studies reporting hepatitis C virus prevalence among the general population in Egypt (Continued)
Salama,09 [78] N/A N/A CS 20 5.0% N/A
Army recruits/Fire brigade personnel
Farghaly,93 [79] N/A N/A CS Army recruits 726 33.0% N/A
Abdel-Wahab,94 [53] 1992 Lower Egypt CS Army recruits 300 22.1% N/A
Quinti,95 [34] 1992-4 Alexandria city, Alexandria CS Fire brigade personnel 541 39.0% N/A
Other general populations
El-Ahmady,94 [10] N/A Cairo city, Cairo CS 292 24.3% N/A
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt PBS 1,422 25.8% 7.7%
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt PBS General population in urban areas 580 23.4% N/A
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt PBS General population: <20 years 414 4.8% N/A
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt PBS General population: 20 – 30 years 163 14.1% N/A
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt PBS General population: 30 – 40 years 253 30.0% N/A
El-Sadawy,04 [61] N/A Sharkia, Lower Egypt PBS General population: >40 years 592 41.9% N/A
Mohamed,04 [80] 1996-7 10 governorates PBS General population 7,357 13.5% N/A
El Zanaty,09 [1] 2008 Nationwide PBS 11,126 14.7% 9.8%













































































Figure 2 Hepatitis C virus (HCV) prevalence among the general population and populations at direct or high risk in Egypt, in studies
conducted pre- and post-2001. A: Graph depicting HCV prevalence among different general population groups. B: Graph depicting HCV
prevalence among different high/direct risk populations. In this figure, we included only stratified HCV prevalence measures, if these stratified
measures were available. Otherwise, we included the overall prevalence measures in the study.
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Table 3 Studies reporting prevalence of hepatitis C virus among populations at direct or high risk of exposure in Egypt





El-Ahmady,94 [10] N/A Cairo city, Cairo CS 51 25.5% N/A
El-Gohary,94 [83] N/A Suez city, Suez CS 140 19.2% N/A
El Gaafary,05 [84] 2002 Cairo city, Cairo CS 309 14.9% N/A
Meky,06 [85] 2002-5 Nile River Delta, Lower Egypt CS 47 78.7% 70.2%
Zakaria,07 [86] 2001-2 Giza, Upper Egypt CS 200 13.0% N/A
Kalil,10 [87] 2004-5 Assuit, Upper Egypt CS Children with viral hepatitis 150 8.7% 8.7%
Talaat,10 [88] 2001-4 Alexandria city, Alexandria/
Abassia, Cairo/Mahalla,
Gharbia, Lower Egypt/Qena
and Aswan, Upper Egypt
CS 4,189 29.8% N/A
Eldin,10 [89] N/A N/A CS 235 4.3% N/A




Khalifa,93 [18] 1990-1 Cairo city, Cairo CS Multi-transfused children 84 55.0% N/A
Abdel-Wahab,94 [53] 1992 Cairo city, Cairo CS Multi-transfused children 71 54.9% N/A
Said,09 [91] N/A Cairo city, Cairo CS Multi-transfused children
with hematological disorders
49 81.6% 49.0%
Said,09 [91] N/A Cairo city, Cairo CS Multi-transfused children with
hematological malignancies
51 17.6% 23.5%
Salama,09 [78] N/A Cairo city, Cairo CS Multi-transfused children 33 15.2% N/A
Kalil,10 [87] 2004-5 Assuit, Upper Egypt CS Multi-transfused children 165 58.2% 41.2%
Tonbary,10 [92] 2000-8 Mansoura, Dakahlia,
Lower Egypt
CS Multi-transfused children 72 11.1% N/A
El-Faramawy,12 [93] N/A Qena, Upper Egypt CS Multi-transfused children 33 39% N/A
Abdelwahab,12 [94] N/A Cairo city, Cairo CS Multi-transfused children 100 40% N/A
Thalassemic patients
El-Nanawy,95 [19] N/A Alexandria city, Alexandria CS Children with thalassemia 18 44.4% N/A
El Gohary,95 [36] 1990-2 Cairo city, Cairo CS Children with thalassemia 45 75.6% N/A
Khalifa,04 [95] 2000-3 Cairo city, Cairo CS Children with thalassemia 56 69.6% N/A
Abdalla,06 [96] 2005 Cairo city, Cairo / Banha,
Qalubiya, Lower Egypt
CS Children with thalassemia 33 60.6% N/A
Omar,11 [97] N/A Cairo city, Cairo CS 174 51.7% 32.2%
Mansour,12 [98] 2009-10 Mansoura, Dakahlia,
Lower Egypt
CS Children with thalassemia 200 19.5% N/A
El-Faramawy,12 [93] N/A Qena, Upper Egypt CS Children with thalassemia 67 48% N/A
Schistosomiasis patients
Bassily,92 [99] N/A Nile River Delta, Lower Egypt CS 31 41.9% N/A
El-Nanawy,95 [19] N/A Alexandria city, Alexandria CS 21 38.1% N/A
El-Zayadi,97 [39] N/A N/A CS 320 16.3% N/A
Zekri,02 [100] 1998-00 Cairo city, Cairo CS 47 42.5% N/A










El-Sabah,11 [101] N/A Rural area, Cairo/ Gharbia,
Lower Egypt
CS 52 7.7% N/A
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Overall, the average HCV prevalence among schisto-
somiasis patients was about 38%. A recent study by
Sabah et al. reported a prevalence of 84.0% among schis-
tosomiasis patients treated with PAT 20 to 30 years ago,
and a prevalence of 7.7% among schistosomiasis patients
treated orally up to 8 years ago [101].
We were able to identify only one study conducted
among IDUs in Egypt [109]. The study was conducted in
Alexandria, among 100 IDUs, and HCV prevalence was
reported to be 63.0% [109].
Figure 2B depicts the range of prevalence within each
subgroup in studies conducted pre and post-2001. No
distinct pattern can be discerned in the distribution of
HCV prevalence pre- and post-2001 within each of the
different subgroups.
Prevalence of HCV among populations at indirect or
intermediate risk of exposure
Populations at indirect or intermediate risk of exposure
to HCV were classified into the following subcategories:
diabetic patients, hospital outpatient attendees, hospitalized
populations, household contacts of index cases (HCV
positive cases), sexually transmitted infection (STI) patients,
periodontal disease patients, prisoners, and populations
working in select professions. Details are shown in
Table S2, see Additional file 1.
Considerable HCV prevalence was reported among
diabetic children in Egypt compared to other countries.
A recent study conducted in 2010, among 692 diabetic
children with an average age of 10.4 years, reported a
prevalence of 2.5% [110]. Previous studies conducted
among diabetic children reported much higher levels of
29.4% [19] and 44.1% [22]. In contrast, HCV prevalence
among adult diabetic patients was 20.0% [100] and 60.3%
[111]. Substantial HCV prevalence was also observed
among patients attending hospitals, ranging between 0%
[87] and 72.8% [112]. We identified one study conducted
among periodontal disease patients reporting a prevalence
of 13.0% [113]. Multiple studies were conducted investi-
gating HCV prevalence among the children, spouses, and
family contacts of HCV positive cases. Studies conducted
among children of index cases usually focused on children
of infected mothers to examine the vertical transmission
of HCV. HCV RNA prevalence among infants born to
HCV positive mothers ranged between 3.8% [28] and
25.0% [29]. HCV prevalence among spouses of index
patients was as high as 35.5% [114]. In a study of family
contacts of index patients, the prevalence was 5.7% [115].
Six studies were conducted among populations in select
HCV-relevant professions (Table S2 of Additional file 1).
HCV prevalence among health care workers averaged
about 17%, whereas among barbers it was 12.3% [116].
Table 3 Studies reporting prevalence of hepatitis C virus among populations at direct or high risk of exposure in Egypt
(Continued)
Schistosomiasis patients
treated orally up to
8 years ago
Hemodialysis patients
Hassan,93 [102] N/A N/A CS 105 67.0% N/A
Abdel-Wahab,94 [53] 1992 Cairo city, Cairo CS 78 46.2% N/A
El-Ahmady,94 [10] N/A Cairo city, Cairo CS 25 84.0% N/A
El Gohary,95 [36] 1990-2 Suez city, Suez and
Ismailia, Lower Egypt
CS 108 70.4% N/A
Gohar,95 [72] N/A N/A CS 64 87.5% N/A
Hassan,00 [103] 1996 Cairo city, Cairo CS 210 59.0% N/A
Shatat,00 [104] 1999 N/A CS 83 78.5% N/A
Gad,02 [105] 1998 Ismailia, Lower Egypt CS 47 72.0% N/A
Zekri,02 [100] 1998-00 Cairo city, Cairo CS 30 56.6% N/A
El Yazeed,06 [106] 2002-4 Cairo city, Cairo CS 40 100.0% N/A
Kandil,07 [22] 2004-6 Cairo city, Cairo CS 31 51.6% N/A
Hammad,09 [25] 2008 Mansoura, Dakahlia,
Lower Egypt
CS 34 94.1% N/A
Attia,10 [107] 2008-9 Cairo city, Cairo CS 206 46.1% N/A
Ibrahim,10 [108] 2007 Cairo city, Cairo CS 100 75.0% N/A
Injection Drug Users (IDUs)
El-Ghazzawi,95 [109] N/A Alexandria city, Alexandria CS 100 63.0% N/A
CS convenience sampling, N/A not available, PAT parenteral antischistosomiasis therapy.
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We were able to identify only one study among prisoners
which reported a prevalence of 31.4% [34].
The range of HCV prevalence within each subgroup in
studies conducted pre- and post-2001 can be observed
in Figure 3A. No distinct pattern can be discerned in the
distribution of HCV prevalence pre- and post-2001
within each of the different subgroups.
Prevalence of HCV among special clinical populations
A large fraction of studies were conducted among different
clinical populations (Table S3 of Additional file 1). Overall,
HCV prevalence was very high across all special clinical
population groups. The average HCV prevalence among
non-Hodgkin’s lymphoma (NHL) patients was roughly
41%, while among orthopedic patients it was about 39%.
HCV prevalence among hepatocellular carcinoma (HCC)
cases ranged between 61.0% and 90.3%, with a higher
prevalence observed among rural versus urban populations
[117]. Three studies were conducted among pediatric
cancer patients [81,118,119]. HCV prevalence among
children with leukemia was 19.0% [118]. HCV prevalence
among patients with pediatric malignancies who had just
ended chemotherapy was 39.6% [119]. More recently,
Sharaf-Eldeen et al. reported HCV prevalence of 43.0%
among children with malignant cancers [81].
No distinct pattern can be discerned in the distribution
of HCV prevalence pre- and post-2001 within each of the
different special clinical population subgroups (Figure 3B).
RNA prevalence
Measures of RNA prevalence are included in Tables 2–3,
and S2-S3 of Additional file 1. RNA prevalence was high
across studies in the different population groups. Higher
RNA prevalence was observed among studies conducted
among high risk groups and special clinical populations
compared to the general population and indirect or
intermediate risk groups. Overall, the average RNA
prevalence among those HCV-antibody positive was ap-
proximately 60%.
Risk factors of HCV
Increasing age, a history of PAT, and residing in rural
areas were by far the most common risk factors or asso-
ciations with HCV infection across studies [26,62].
Other common risk factors were related to healthcare
settings such as history of blood transfusions, invasive
procedures, injections, perinatal care, and dental work
[15,61,62,69,71,82,87]. Saleh et al. reported a greater
risk for incident infection among women whose babies
were delivered by a physician rather than by a nurse or
a traditional birth attendant, in a health facility rather
than at their home, and in women having complicated
vaginal deliveries [15]. Among children, incident infection
was associated with hospitalization and low birth weight
[17]. Community and informal health provider related
exposures such as circumcision, cautery, and injections
were also associated with HCV infection [62,82,120]. A
number of studies have also suggested intrafamilial trans-




Twenty six of the 87 general population studies had the
year of data collection missing. The results of our paired
t-test identified a mean difference of 3.1 years (95% CI:
2.6 to 3.6) between the year of publication and the year
of data collection, for studies with both values present.
We applied this time lag to estimate the year of data
collection for studies missing this value.
In the univariate linear regression analyses for each
subgroup separately, blood donors were the only sub-
group showing a statistically significant change in HCV
prevalence over time (p-value of 0.001). Table S4, see
Additional file 1, reports the results of the univariate
analyses.
In the multivariate linear regression analysis for the
combined general population subgroups, there was no
evidence of a statistically significant decline in HCV
prevalence over time (p-value of 0.215). HCV prevalence
in the general population changed at a rate of −0.24%
per year (95% CI: -0.63 to 0.14). Figure 4 displays the
trend in HCV prevalence with time in each of the eight
general population subgroups.
Direct or high risk population model
Twenty five of the 46 direct or high risk population studies
had the year of data collection missing. The results of
the paired t-test identified a mean difference of 3.3 years
(95% CI: 4.0 to 2.6) between the year of publication and
the year of data collection. We applied this time lag to
estimate the year of data collection for studies missing
this value.
As was the case for the general population univariate
and multivariate analyses, there was no evidence of a
statistically significant decline in HCV prevalence over
time for each high risk population subgroup (results
not shown) and in the high risk population as a whole
(p-value of 0.426). HCV prevalence in the high risk popu-
lation declined at a rate of −0.38% per year (95% CI: -1.35
to 0.58). Figure S5, of Additional file 1, displays the trend
in HCV prevalence with time in each of the five high risk
subgroups. IDUs were excluded from this figure as there
was only one observation.
Discussion
We have systematically reviewed HCV infection prevalence
and incidence across the different population groups in
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Egypt. The results of our study indicate that Egypt is
enduring a large HCV disease burden, and is likely to be
the most affected nation worldwide by this infection. HCV
prevalence and incidence across the diverse population
groups were found to be much higher than those in other
countries around the globe [3,122,123]. This makes HCV
and its complications one of the leading public health
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Figure 3 Hepatitis C virus (HCV) prevalence among populations at indirect or intermediate risk and special clinical populations in Egypt, in
studies conducted pre and post the 2001. A: Graph depicting HCV prevalence among different populations at indirect or intermediate risk in Egypt.
B: Graph depicting HCV prevalence among different special clinical populations1 in Egypt. In this figure, we included only stratified HCV prevalence
measures, if these stratified measures were available. Otherwise, we included the overall prevalence measures in the study. 1Acronyms: BC: bladder
cancer, CLD: chronic liver disease, CRF: chronic renal failure, CV: cutaneous vasculitis, GIB: gastrointestinal bleeding, GN: glomerulonephritis, HCC:
hepatocellular carcinoma, HCCA:hilarcholangiocarcinoma, HL: Hodgkin’s lymphoma, KTP: kidney transplant patients, LD: liver diseae, LP:lichen planus,
MDS: myelodysplastic syndrome NHL: non-Hodgkin’s lymphoma, RHD: rheumatic heart disease, SLE: systematic lupus erthymatosus.
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The results of this synthesis indicate that Egypt has
endured a large HCV epidemic at the national level, and
that there is substantial endemic HCV transmission in this
country. HCV prevalence is at high levels across essen-
tially all population groups, demonstrating the expansive
nature of this epidemic, and that it is not isolated to
specific population groups or geographic areas.
Despite being a major driver of HCV incidence and
prevalence in many countries [124], the relative contri-
bution of IDUs to HCV incidence and prevalence in
Egypt is much smaller than that in other countries. This
is because of the specific context of HCV in Egypt,
where HCV transmission is associated with medical
exposures in the context of a general population HCV
epidemic. Still, there is a contribution from injecting drug
use to HCV transmission that is, in terms of absolute
scale, comparable to other countries. The prevalence of
injecting drug use in Egypt is estimated to be 0.21% [125],
and according to the only study we found, HCV preva-
lence among IDUs is 63% [109]. Considering that HCV
prevalence in the population is 14.7% [1], injecting drug
use may explain at most only about 1% of the national
HCV prevalence in Egypt.
It is widely believed that the PAT campaigns to control
schistosomiasis are the major drivers of the HCV epidemic
in Egypt [5]. During the early twentieth century, schisto-
somiasis was highly prevalent in Egypt, especially in rural
areas [6]. From the 1950s to the early 1980s, the Egyptian
Ministry of Health led large-scale campaigns to control the
disease [6]. Millions of people were treated with intraven-
ous injections of tartar emetic, before an oral drug replaced
this standard of care across the country in the 1980s [5].
Reuse of glass syringes and lax sterilization practices during
PAT campaigns appear to have caused widespread infection
with HCV, which by the 1990s, had replaced schistosomia-
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Figure 4 Time trend of hepatitis C prevalence among the different general population subgroups in Egypt.
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Our study supports a major role for the PAT cam-
paigns in driving HCV incidence. Different studies have
shown a dramatic increase in HCV prevalence with
age; a cohort effect that may be explained, at least in
part, by the early association between PAT and HCV
transmission [26,60-62,82,127]. Our results also highlight
gender and geographical differences in HCV prevalence
[36,64,71,75,128,129], with higher prevalence observed
in males and rural dwellers compared to females and
individuals living in urban areas. These differences may
also be in part attributed to the PAT campaigns, as rural
areas and males were more affected by the schistosomiasis
disease burden and hence were main targets of these
campaigns [5].
However, the totality of the evidence synthesized here
suggests that the PAT campaigns are one driver among
others of HCV transmission in Egypt, and that substantial
HCV transmission is still ongoing. High HCV prevalence
is found among hospitalized and the special clinical popu-
lations; populations that have experienced various facility-
based medical procedures. Elevated HCV prevalence is
also found among individuals exposed to even minor
medical care procedures, within and beyond established
health care facilities. Community studies have found
strong correlations between HCV infection and different
medical exposures such as injections, blood transfusions,
surgical procedures, perinatal care, and dental treatment
[15,61,62,69,71,82,87].
HCV prevalence among children, in particular, highlights
the ongoing transmission of HCV in Egypt. Not only
were these children born well after the end of the PAT
campaigns, but also a large fraction of them were born
after the implementation of the more stringent infection
control measures in the country. Nevertheless, consider-
able prevalence levels are found among children in
multiple studies. These studies suggest that children have
been exposed to HCV vertically through mother-to-child
transmission [24,25,27-29] (high RNA prevalence was
documented among infants of HCV positive mothers,
ranging between 3.8% and 11.1% [24,25,27-29,130,131]),
or horizontally possibly through household exposures
[14,114,115,121,131]. Medical exposures to HCV at a very
young age have been also indicated [19,22,110,132]. High
HCV levels were reported among thalassemic children
[19,96,133], children on hemodialysis [22,132] and diabetic
children [19,22,110].
HCV prevalence among the mothers of infected chil-
dren, who tend to be young themselves, has been also
associated with medical exposures and/or household
exposures [24,25,27,28]. Injecting drug use is unlikely
to contribute much to HCV prevalence among these
mothers, given the context of the HCV epidemic in
Egypt. Moreover, injecting drug use among women in
the Middle East and North Africa region is believed to
be marginal with only about 10% or less of IDUs being
females in this region [134-136].
Results of our time trend analysis suggest that, contrary
to expectations, there appears to be a small decline,
though statistically not significant, in HCV prevalence
over time in the general population and high risk popula-
tion in Egypt. In the univariate subgroup-specific analyses,
only blood donors have shown a statistically significant
decline in HCV prevalence. However, this decline is
difficult to interpret since recruitment of blood donors
changed over time, particularly by excluding HCV positive
individuals. While it can take a long time for the preva-
lence of HCV to decline after the PAT exposures, this fact
may not be sufficient to explain the lack of tangible
decline. Egypt’s population has almost doubled in the past
two to three decades since the epidemic was first discov-
ered, and well after the end of the PAT campaigns. The
large influx of uninfected birth cohorts does not appear to
have reduced HCV prevalence, possibly suggesting that
HCV incidence has not declined as expected following the
end of the PAT campaigns and adoption of more stringent
infection control measures.
Another potential explanation for the lack of substantial
decline in incidence is the very high baseline HCV preva-
lence in the country. For a given mode of transmission,
such as reuse of unclean needles or syringes, the transmis-
sion risk is dependent on the probability that the needle/
syringe was used previously on an HCV infected person,
which is HCV RNA prevalence. Even if the prevalence of
the modes of transmissions in Egypt today is similar to
other neighboring countries, the high background preva-
lence can drive much more incidence. In neighboring
Libya for example, with an HCV RNA prevalence of less
than 1% [134,137], a reuse of an unclean needle is more
than ten-fold less likely to lead to an HCV transmission
than in Egypt where HCV RNA prevalence is 9.8% [1].
Our study identified the lack of an empirical nationally-
representative incidence study. It is a priority to document
current HCV incidence rate in the population, which
continues to be the most critical open question in HCV
epidemiology in Egypt today, and is subject to much
debate [127,138]. A recent mathematical modeling study,
based on the EDHS data, estimated that the average HCV
incidence rate over the lifetime of the living Egyptian
population cohort to be 6.9 per 1,000 person-year [7]. This
estimate however does not capture the temporal trend in
HCV incidence rate and may not be representative of
the current level of HCV transmission. A recent study
suggested that current HCV incidence rate is about 2.0
per 1000 person-year [127].
While the evidence for an epidemic at the national level
is overwhelming, some of the potential drivers of this
epidemic, such as the PAT campaigns and contaminated
blood, are no longer present. Therefore, it seems plausible
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that HCV incidence rate has declined drastically in the
last two decades since the discovery of the epidemic in
1991–1992 [30,139], as Breban et al. have recently
suggested through their incidence estimate [127]. Never-
theless, our study could not identify a signature for a
major reduction in incidence, and the totality of evidence
points towards substantial ongoing HCV transmission,
though the precise scale of which is not yet known.
In terms of limitations, there was an element of subject-
ivity in classifying different studies into different population
subgroups. For example, studies conducted in rural
children were classified under children even though
they fall into two subgroups: rural populations and
children. Furthermore, there was variability in the
diagnostic assays used across the studies. Earlier studies
typically reported the use of 1st and 2nd generation ELISA
tests, which lack the sensitivity and specificity of the 3rd
generation ELISA tests. Such variability in assays may
impact the representativeness of the reported prevalence
measures. There was also considerable variability in meth-
odology and quality among the studies assessed. Most of
the studies identified were cross-sectional or case–control
in study design. Sample size varied widely across studies.
The sampling was most often convenience sampling,
though several studies have used probability-based
samples [1,61,69], most notably the EDHS conducted
in 2008 [1]. For a fraction of the studies the year of
data collection was not available but was estimated
using the year of publication, this may affect the time
trend analysis. Given that only statistically significant
risk factors were extracted, this may have introduced a
positive-association selection bias in our reporting of
risk factors.
Conclusions
Our study highlights that Egypt is confronted with an
HCV disease burden of historical proportions. An HCV
epidemic at the national level must have occurred with
substantial transmission still ongoing today. As opposed
to other countries where HCV dynamics is focused in
specific high risk groups, such as IDUs, HCV transmission
in Egypt has reached diverse population groups including
those not conventionally identified to be at risk of infec-
tion. HCV transmission appears to be focused in formal
and informal health care settings, though transmission
may be occurring in the community and at the household
level, but through poorly-identified exposures.
HCV prevention in Egypt must be a national priority.
Policymakers and public health and medical care stake-
holders need to introduce and implement further preven-
tion measures targeting the iatrogenic transmission
routes, such as very stringent infection control practices.
Scientific research needs to be expanded to measure
current HCV incidence rate and to identify precisely the
modes of HCV transmission in medical care, community,
and household settings. Such studies will pave the way for
effective prevention interventions that can be developed,
experimentally tested, and implemented. It is also essential
to develop cost-effective strategies for treatment and case
management of the large pool of 5–7 million chronically
infected persons with HCV in Egypt.
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